These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 388793)

  • 21. Genitourinary tumors and immunology.
    Lange PH
    Proc Inst Med Chic; 1978; 32(4):58-9. PubMed ID: 86188
    [No Abstract]   [Full Text] [Related]  

  • 22. [Secretion and absorption on O erythrocytes of the Atri substance].
    Marcelli-Barge A; Poirier JC; Benajam A; Tilz GP; Dausset J
    C R Seances Soc Biol Fil; 1974; 168(2-3):199-206. PubMed ID: 4282273
    [No Abstract]   [Full Text] [Related]  

  • 23. Follow-up surveillance strategies for genitourinary malignancies.
    Evans CP
    Cancer; 2002 Jun; 94(11):2892-905. PubMed ID: 12115377
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Studies on multiple mucosal biopsy in patients with bladder cancer. 3. Evaluation of ABH antigenicity in specimens of multiple mucosal biopsy and transitional cell carcinoma of the bladder].
    Igawa M
    Hinyokika Kiyo; 1986 Nov; 32(11):1649-62. PubMed ID: 3825814
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Review of 43 autopsy cases of urogenital malignant tumors].
    Yuasa M; Kojima K; Furukawa A; Tamura M; Kawanishi Y; Numata A; Imagawa A
    Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-3):1947-53. PubMed ID: 2730088
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Serum copper and zinc levels in patients with malignant neoplasm of the urogenital tract].
    Sanada S; Ogura K; Kiriyama T; Yoshida O
    Hinyokika Kiyo; 1985 Aug; 31(8):1299-316. PubMed ID: 4083194
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Theoretical principles of clinical tumor immunology].
    Umanskiĭ IuA
    Vopr Onkol; 1975; 21(9):106-15. PubMed ID: 1103468
    [No Abstract]   [Full Text] [Related]  

  • 29. Surgeons: A Future Role in Clinical Trials?
    Rusch VW
    Oncologist; 1997; 2(3):V-VI. PubMed ID: 10388050
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Monoclonal antibodies to human prostate and bladder tumor-associated antigens.
    Starling JJ; Sieg SM; Beckett ML; Schellhammer PF; Ladaga LE; Wright GL
    Cancer Res; 1982 Aug; 42(8):3084-9. PubMed ID: 7046915
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Molecular staging of testicular cancer using polymerase chain reaction of the testicular cancer-specific genes].
    Nonomura N; Imazu T; Harada Y; Nozawa M; Ono Y; Fukui T; Nishimura K; Okuyama A
    Hinyokika Kiyo; 1999 Aug; 45(8):593-7. PubMed ID: 10500969
    [TBL] [Abstract][Full Text] [Related]  

  • 32. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility.
    American Society of Clinical Oncology
    J Clin Oncol; 2003 Jun; 21(12):2397-406. PubMed ID: 12692171
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Current concepts of tumor immunology. II. Tumor immunodetection.
    Krause CJ; Nysather JO
    Ann Otol Rhinol Laryngol; 1977; 86(6 Pt 1):871-4. PubMed ID: 74228
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Molecular structure of human chorionic gonadotropin: new functions in immunology, endocrinology and oncology].
    Dirnhofer S; Berger P
    Praxis (Bern 1994); 2002 May; 91(19):845-8. PubMed ID: 12071085
    [No Abstract]   [Full Text] [Related]  

  • 35. Current and proposed molecular diagnostics in a genitourinary service line laboratory at a tertiary clinical institution.
    Udager AM; Alva A; Mehra R
    Cancer J; 2014; 20(1):29-42. PubMed ID: 24445763
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Introduction to the problem of markers in urologic oncology].
    Base J
    Rozhl Chir; 1990 Nov; 69(11):750-3. PubMed ID: 2136439
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunological status as a criterion for operability of genitourinary cancers.
    Allison RC; Leadbetter GW
    J Surg Oncol; 1975; 7(1):81-3. PubMed ID: 1237070
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Immunologic assessment of urogenital carcinoma].
    Chou YH; Huang CH; Chiang CP
    Taiwan Yi Xue Hui Za Zhi; 1983 Nov; 82(11):1163-9. PubMed ID: 6584541
    [No Abstract]   [Full Text] [Related]  

  • 39. [Occult carcinoma in urology. Nosography and diagnosis].
    Alberti C; Sacchini P; Cortellini P
    Minerva Urol Nefrol; 1990; 42(2):85-93. PubMed ID: 2203166
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Overview on new immunologic markers for diagnosis of cancer.
    Herberman RB
    Cancer; 1978 Sep; 42(3 Suppl):1595-600. PubMed ID: 361206
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.